An inherited fibrinogen variant, fibrinogen Bern I, was isolated from plasma of an asymptomatic woman. Routine coagulation studies showed prolonged thrombin and reptilase clotting times. Fibrinogen concentration was diminished when determined by a functional assay, but was normal by the heat precipitation method. The release of fibrinopeptides A and B was not delayed. Two-dimensional gel electrophoresis of mercaptolyzed fragments D of fibrinogen, obtained by digestion with plasmin, showed an abnormal electrophoretic mobility in the y-chain remnants of fragments D, and D, from fibrinogen Bern 1, whereas conversion of D, to D, by plasmin resulted in the loss of the ONGENITAL dysfibrinogenemia defines an inherited C functional defect caused by structural alteration in the fibrinogen molecule. Most dysfibrinogenemias have thus far been detected by virtue of a prolonged thrombin clotting time and, therefore, mainly represent variants with defective fibrinogen to fibrin conversion. More than 240 abnormal fibrinogen variants have been described.' In a large proportion of abnormal fibrinogens, the defective release of fibrinopeptides A and/or B is caused by an amino acid substitution interfering with the thrombin-induced cleavage of the peptide bonds ACI 16-17 or BP 14-15, Furthermore, in several fibrinogen variants, the functional defect is associated with an abnormal or absent amino terminal polymerization site. Polymerization of fibrin is initiated by exposure of amino terminal binding sites, Gly-Pro-Arg (a-chain) and Gly-His-Arg (P-chain) after proteolytic cleavage of fibrinopeptides A and B, re~pectively.~,~ Fibrin monomers interact with complementary carboxy terminal domains of neighboring fibrin(ogen) m01ecules.~~' The carboxy terminal region of the y-chain plays an important role in fibrin monomer polymerization. The synthetic peptide Gly-Pro-Arg-Pro, an analogue of the amino terminus of the fibrin a-chain, was found to bind to fragment D, and to inhibit polymerization of fibrin monomers.* However, peptides with the sequence Gly-Pro-Arg did not bind to the plasmin-generated fragment D, lacking the carboxy terminal 109 residues of the y-chain. Thus, the carboxy terminal third of the y-chain is supposed to bear the polymerization Clinical Chemistry Laboratory, Inselspital, University of Bern, Switzerland. Submitted March 24, 1993; accepted May 20, 1993. Supported by Swiss National Science Foundation Grant No. 32-28785.90 0006-4971/93/8207-0110$3.00/0 abnormal charge, suggesting that the structural abnormality in this variant is located in the region y 303 through 356. The molecular defect in fibrinogen Bern I was identified by sequence analysis of genomic DNA amplified by polymerase chain reaction and cloned in M13mpl9. 'The triplet AAC coding for asparagine at position y 337 was found to be substituted by AAA coding for lysine. We conclude that the substitution y 337 Asn -+ Lys in fibrinogen Bern I is responsible for defective polymerization of fibrin monomers and for impaired protection by calcium against plasmic degradation.
C functional defect caused by structural alteration in the fibrinogen molecule. Most dysfibrinogenemias have thus far been detected by virtue of a prolonged thrombin clotting time and, therefore, mainly represent variants with defective fibrinogen to fibrin conversion. More than 240 abnormal fibrinogen variants have been described. ' In a large proportion of abnormal fibrinogens, the defective release of fibrinopeptides A and/or B is caused by an amino acid substitution interfering with the thrombin-induced cleavage of the peptide bonds ACI 16-17 or BP 14-15, Furthermore, in several fibrinogen variants, the functional defect is associated with an abnormal or absent amino terminal polymerization site. Polymerization of fibrin is initiated by exposure of amino terminal binding sites, Gly-Pro-Arg (a-chain) and Gly-His-Arg (P-chain) after proteolytic cleavage of fibrinopeptides A and B, re~pectively.~,~ Fibrin monomers interact with complementary carboxy terminal domains of neighboring fibrin(ogen) m01ecules.~~' The carboxy terminal region of the y-chain plays an important role in fibrin monomer polymerization. The synthetic peptide Gly-Pro-Arg-Pro, an analogue of the amino terminus of the fibrin a-chain, was found to bind to fragment D, and to inhibit polymerization of fibrin monomers.* However, peptides with the sequence Gly-Pro-Arg did not bind to the plasmin-generated fragment D, lacking the carboxy terminal 109 residues of the y-chain. Thus, the carboxy terminal third of the y-chain is supposed to bear the polymerization site. Recently, the binding site for Gly-Pro-Arg was located to the y-chain residues 337 through 379 by photoaffinity labeling.' Functionally abnormal fibrinogens with structural defects in the y-chain include variants with amino acid substitutions between positions y 275'"," and y 375."
In the present study, we identified the defect in fibrinogen Bern I, a dysfunctional variant characterized by delayed clotting in the absence of calcium ion^.'^,'^ Residue y 337 Asn was found to be replaced by Lys, which seems to be responsible for delayed polymerization of fibrin monomers derived from this variant. 
MATERIALS AND METHODS

Materials
Two-dimensional gel electrophoresis of plasmin-digestedfibrinogenfragments D,, D,, and D,. Normal fibrinogen and fibrinogen
Bern I were digested by plasmin (Kabi, Stockholm, Sweden) in the presence of 10 mmol/L CaCl,. The resulting fragment D, was isolated by affinity chromatography on ly~ine-agarosel~ and dialyzed against 0.05 mol/L triethanolamine, 0.1 mol/L NaCl, 10 mmol/L EGTA, pH 7.4. Fragment D, (2 mg/mL) was incubated for 3 hours at 37°C with 0.3 U/mL plasminogen (Kabi) and 6 U/mL streptokinase (Kabi). The resulting fragments D,, D,, and D, were reduced with 2% dithiothreitol (Fluka) and separated by isoelectric focusing and sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis according to Reber et aLzo DNA isolation from whole blood. Twenty milliliters fresh EDTA (final concentration 4 mmol/L) blood of the proposita's mother were centrifuged for 20 minutes at 1,800g at room temperature. Plasma was aspirated to approximately 5 mm above the buffy coat and discarded. Ice-cold lysis buffet' (0.32 mol/L sucrose, 10 mmol/L Tris-HCI, 5 mmol/L MgCl,, I% Triton X-100, pH 7.5) was added to the cell pellet to a final volume of 50 mL. The suspension was mixed gently by inverting, set on ice for 15 minutes, and then centrifuged for 15 minutes at 1,800g and 4°C. The supernatant was discarded, and the pellet resuspended in fresh lysis buffer to a final volume of 50 mL. The suspension was centrifuged immediately for 10 minutes at 1,SOOg (4"C), and the resulting nuclear pellet was resuspended in 3 mL of a solution containing 10 mmol/L Tris-HCI, 1 mmol/L EDTA, 0.5% SDS, pH 8.0, 500 pg/mL proteinase K and 50 pg/mL RNase. Digestion was performed for 3 hours at 50°C. The DNA was then extracted with phenol-chloroform according to Gustafson et aIz2 and precipitated with 2 volumes of ice-cold ethanol after addition of0.2 vol of 10 mol/L ammonium acetate. High molecular weight DNA was washed twice with 70% ethanol, lyophilized, and dissolved in 1.5 mL 10 mmol/L Tris-HC1, 1 mmol/L EDTA, pH 8.0. The absorbance was measured at 260 nm, and the calculated yield of DNA was approximately 360 pg from 20 mL fresh blood.
Amplification by polymerase chain reaction (PCR). A 3 12-bp fragment of the fibrinogen y-chain gene23 containing the DNA sequence of exon VI11 coding for amino acids 259 through 350 was amplified with the following 22-base-long primer pair: sense primer, 5'-TCAGCATGTGATGGTTGTATTT-3'; antisense primer, 5'-CTTGGTAATAAACTCCATTGAG-3'. These oligonucleotide primers had been synthesized by L. Edenharter (Institute of Microbiology, Bern, Switzerland) using an Applied Biosvstem 38 1A DNA synthesizer by the P-cyanoethyl phosphoramidine method. Amplification was performed in a 100 pL reeztion volume containing 1 pg genomic DNA, 4 U Taq DNA polymerase, 200 pmol/L each of d-adenosine triphosphate (dATP), d-cytidine triphosphate (dCTP), d-thymidine triphosphate (dTTP), d-guanosine triphosphate (dGTP), 0.1 pmol/L, and 0.5 pmol/L of sense and antisense primer, respectively, in 10 mmol/L Tris-HC1, at 25"C, 50 mmol/L KCI, 1.5 mmol/L MgCl,, and 0.01% (wt/vol) gelatin, pH 8.4. Sixty cycles of amplification were performed by using a DNA thermal cycler (Perkin-Elmer-Cetus, Nonvalk, CT). Incubation times for each cycle were 1 minute at 94"C, I minute at 45"C, and 2 minutes at 72°C. Similar procedure was used for amplification of a 290-bp fragment of the y-chain gene, containing exon IX and coding for amino acids 35 I through 407, using the following pair of 2 I-mer primers, 5'-GCACTTCGTAATAGACAGCTC-3' and 5'-CATATTCTGTTTCCGCAGGGT-3' (Microsynth, Windisch, Switzerland). Incubation times were 1 minute at 9 4 T , 1 minute at 47"C, and 2 minutes at 72°C for a total of 60 cycles. The size ofthe PCR products was examined using a 123-bp ladder-size standard in a 1.4% (wt/vol) agarose gel stained with 0.66 pg/mL ethidium bromide in 0.09 mol/L Tris-borate, 2.6 mmol/L EDTA, pH 8.3.
Molecular cloning and sequencing of normal and variant exon VIII offibrinogen Bern I. Amplification of double-stranded exon VI11 fragment was performed under similar conditions as described above with the following modifications: 0.42 pmol/L each of sense and antisense primer, 2 U Taq DNA polymerase, and 50 cycles. The PCR product was purified on a QIAGEN-tip 5 mini column according to manufacturer's instructions and cloned into Sma I polycloning site of M 1 3 m~1 9 .~~ Individual clones were sequenced using the 17-mer sequencing primer (-40) and [c~-~'S] dATP by using the Sequenase Version 2.0 kit. Dideoxynucleotide termination reaction products were run on a 8% polyacrylamide sequencing gel in a Sequi-Gen Nucleic Acid Sequencing Cell from Bio Rad (Richmond, CA). The gel was dried on a Slab Gel Dryer SE 1160 (Hoefer Scientific Instruments, San Francisco, CA), and autoradiography was performed using 3M Trimax medical imaging film (3M, Ferrani, Italy).
RESULTS
Case report. Dysfibrinogen Bern I was discovered in
1978 in a 24-year-old woman without a history of bleeding or thrombotic tendency. Upon admission to the hospital, her TT and RT were found to be prolonged (Table 1) . Fibrinogen concentration determined by the functional assay was markedly decreased, whereas the heat precipitation method indicated normal fibrinogen values. Family members were studied, and their laboratory parameters were consistent with the diagnosis of hereditary dysfibrinogenemia. The proposita, her sisters, and her brother have inherited the functionally abnormal fibrinogen from their mother, whereas the father was not affected. Neither the mother nor any of her children had bleeding symptoms or thrombotic episodes.
The kinetics of fibrinopeptide release by thrombin from the normal and the variant fibrinogen are shown in Fig 1. The amounts of fibrinopeptides A and B cleaved from normal fibrinogen within 1 hour were taken as 100%. Our results indicate that delayed clotting of fibrinogen Bern I cannot be ascribed to an impaired fibrinopeptide cleavage by thrombin, because fibrinopeptide A cleavage from fibrinogen-Bern I appeared to proceed even faster than that from normal fibrinogen, and fibrinopeptide B release was normal. These results suggest that the structural defect is not situated in the amino terminal domain of fibrinogen near the thrombin cleavage sites. AmplSfication and DNA sequence analysis. Two DNA fragments of 3 12-and 290-bp, comprising exons VI11 and IX and coding for amino acids 259 through 350 and 351 through 407 of the y-chain, respectively, were amplified by asymmetric PCR. The DNA sequence of the amplified exon IX was indistinguishable from the normal DNA sequence. The sequence analysis of exon VI11 showed the presence of two bands at the same migration distance with about equal radioactivity (data not shown), suggesting that the patient is heterozygous for the mutation AAC + AAA, corresponding to amino acid substitution y 337 Asn + Lys. To improve quality of the sequence analysis of exon VIII, cloning experiments were performed. Five of eighty-eight clones contained the insert. The sequence of two of them, both representing antisense strands from either normal or abnormal y-chain gene fragments, is shown in Fig 3. A guanine in the normal amplified exon VI11 was found to be substituted by thymine. Thus, the single base substitution altered the codon in the sense strand for y 337 Asn (AAC) to Lys (AAA). 
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DISCUSSION
An abnormal fibrinogen variant, denoted as fibrinogen Bern I, was detected in a clinically asymptomatic woman. Thrombin and reptilase clotting times were prolonged. Fibrinogen concentration was decreased when measured by the functional assay but was normal by the heat precipitation method (Table 1) . Family study confirmed the hereditary nature of this dysfibrinogenemia. Fibrinogen Bern I was isolated from the proposita's plasma and displayed normal fibrinopeptide A and B release (Fig 1) . Fibrinopeptide A was cleaved even faster from fibrinogen Bern I than from normal fibrinogen. As shown previou~ly,'~ the rate of fibrin monomer polymerization was decreased at low concentration ofcalcium ions, but it was fully normalized only at high (5 mmol/L) calcium concentration, suggesting that calcium binding site might be functionally inadequate in fibrinogen Bern I. A complete correction of fibrin polymerization by high concentration of calcium has also been observed in fibrinogen Osaka VI2, a variant with an amino acid substitution y 375 Arg + Gly, lacking 2 of the 3 high-affinity calcium binding sites. It is obvious that the functional defect in fibrinogen Bern I cannot be explained solely by deficient calcium binding, because in the presence of EDTA, the defective clotting of fibrinogen Bern I even became more prominent. l4 Our previous experiments showed impaired protection by calcium of the carboxy terminal portion of the y-chain of fibrinogen Bern I against proteolytic degradation by plasmin.I4 Similarly, in fibrinogen variants Haifa (y 275 Arg + His),2' Osaka V (y 375 Arg + Gly)," Kyoto I (y 308 Asn + LYS)?~ and Vlissingen (deletion y 3 19 Asn and 320 Asp),27 the carboxy terminus of the y-chain was degraded by plasmin despite the presence of Ca2+ ions. Thus, our former observations with fibrinogen Bern I hinted at a structural defect in the carboxyterminal part of the y-chain, affecting calcium binding.
The carboxy terminal portion of the y-chain not only contains one high-affinity binding site for Ca2+ ions, tentatively located between residues y 3 11 through 336,28 but also appears to be involved in polymerization of fibrin monomers. Synthetic peptides, beginning with the amino terminal sequence (Gly-Pro-Arg) of the fibrin a-chain were shown to bind strongly to plasmin-generated fragment D,, whereas no binding occurred to fragment D,, which lacks the carboxy terminal 109 residues ofthe y-chain.' The binding site for Gly-Pro-Arg has recently been more precisely ascribed to y-chain residues 337 through 379.9 Using twodimensional electrophoresis in polyacrylamide gel of the reduced fragments D,, D,, and D, derived from fibrinogen Bern I by plasmic degradation. a y-chain remnant of fragment D, with an increased isoelectric point was noted (Fig  2) . whereas the abnormal charge disappeared during conversion of fragment D, to D, suggesting that the molecular defect is situhed within the amino acid through 356, which corresponds to the from fragment D, by plasmin. To identify the structural defect in fibrinogen Bern 1. PCR was used for amplification and sequence analysis of the exons VI11 and IX coding for amino acid residues 259 through 350 and 35 1 through 407 of the y-chain," respectively. The DNA sequence of the amplified exon IX was indistinguishable from the normal DNA sequence. Direct sequence analysis of exon VI11 showed the presence of two bands at the same migration distance, corresponding to amino acid substitution y 337 Asn -Lys (AAC + AAA).
The purified double-stranded PCR-derived fragment was cloned and subjected to sequence analysis. Normal and mutated alleles of fibrinogen Bern I were obtained, showing a G + T transition in the noncoding strand (Fig 3) . Thus, codon AAC in the sense strand of the exon VI11 of the ychain gene was substituted by AAA, leading to a replacement of Asn by Lys at position y 337 in fibrinogen Bern I.
In conclusion, PCR was used to determine the structural defect in the abnormal fibrinogen variant Bern I. A new point mutation was found in the y-chain of fibrinogen Bern I, leading to the substitution of the amino acid y 337 Asn by Lys. This mutation results in defective expression of the polymerization site and in impaired protection by calcium ions against plasmic digestion of the carboxy terminus of the y-chain.
